Cagrilintide: What the Research Says About the Amylin Analogue
Cagrilintide is a long-acting amylin analogue that has become one of the most discussed compounds in metabolic research. This overview explains what it is and how the scientific literature describes it, strictly for research context.
What is cagrilintide?
Amylin is a hormone co-secreted with insulin. Cagrilintide is a synthetic, acylated analogue engineered for a long half-life, allowing infrequent dosing in study designs. In the literature it is grouped with the newer generation of metabolic research peptides alongside the GLP-1 class.
How amylin analogues are studied
Research on amylin analogues examines receptor signalling and satiety pathways in preclinical and clinical models. Figures reported in trials should be read as study observations attributed to the specific trial, not outcomes to expect.
Cagrilintide in combination research
Much of the interest comes from combination studies pairing cagrilintide with the GLP-1 analogue semaglutide (referred to in the literature as "CagriSema"). These are research combinations reported in the scientific record, not personal-use protocols.
How it relates to other metabolic research peptides
For context on adjacent compounds, see our overview of the GLP-1/glucagon dual agonist mazdutide and our guide to reconstituting GLP-1 research peptides.
Handling and storage
Like most research peptides, cagrilintide ships as a lyophilized powder that is reconstituted for laboratory work with bacteriostatic water. Review proper sterile technique and use the reconstitution calculator to work out concentrations.
Quality and verification
Because purity matters in research, understand how peptide purity is verified by HPLC and mass spectrometry before relying on any material.
Research use only. This article is educational and is not medical, legal, or financial advice. The compounds discussed are not approved for human or veterinary use, consumption, or therapeutic application.